awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q37704373-C25AACA6-0E0B-4C31-A143-B5BC1D82AB68
Q37704373-C25AACA6-0E0B-4C31-A143-B5BC1D82AB68
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37704373-C25AACA6-0E0B-4C31-A143-B5BC1D82AB68
JAK inhibitors suppress t(8;21) fusion protein-induced leukemia.
P2860
Q37704373-C25AACA6-0E0B-4C31-A143-B5BC1D82AB68
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37704373-C25AACA6-0E0B-4C31-A143-B5BC1D82AB68
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
ae301c67dff0be8598a72e2f5a544201b408a8a1
P2860
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.